DE4331711C2 - Lösung zur Perfusion, Konservierung und Re-Perfusion von Organen - Google Patents
Lösung zur Perfusion, Konservierung und Re-Perfusion von OrganenInfo
- Publication number
- DE4331711C2 DE4331711C2 DE4331711A DE4331711A DE4331711C2 DE 4331711 C2 DE4331711 C2 DE 4331711C2 DE 4331711 A DE4331711 A DE 4331711A DE 4331711 A DE4331711 A DE 4331711A DE 4331711 C2 DE4331711 C2 DE 4331711C2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- reduced glutathione
- solution according
- perfusion
- glutathione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000010412 perfusion Effects 0.000 title claims description 11
- 210000000056 organ Anatomy 0.000 title description 16
- 238000004321 preservation Methods 0.000 title description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 38
- 108010024636 Glutathione Proteins 0.000 claims description 27
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 239000001301 oxygen Substances 0.000 claims description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 14
- 230000010410 reperfusion Effects 0.000 claims description 14
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 230000007717 exclusion Effects 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 4
- 229940099584 lactobionate Drugs 0.000 claims description 4
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 150000001450 anions Chemical class 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229930195712 glutamate Natural products 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 229960000958 deferoxamine Drugs 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 150000002739 metals Chemical class 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 description 54
- 229960003180 glutathione Drugs 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 8
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 7
- 229960004308 acetylcysteine Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000007792 addition Methods 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002631 hypothermal effect Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- -1 oxygen radicals Chemical class 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940123457 Free radical scavenger Drugs 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000008148 cardioplegic solution Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- GZFOMNDCXQBAAX-BQBZGAKWSA-N (2s)-2-amino-5-[[(2r)-1-[(2-methoxy-2-oxoethyl)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound COC(=O)CNC(=O)[C@H](CS)NC(=O)CC[C@H](N)C(O)=O GZFOMNDCXQBAAX-BQBZGAKWSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001101 cardioplegic effect Effects 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940072417 peroxidase Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000036313 post-ischemic recovery Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94607392A | 1992-09-18 | 1992-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE4331711A1 DE4331711A1 (de) | 1994-03-24 |
| DE4331711C2 true DE4331711C2 (de) | 2001-05-03 |
Family
ID=25483919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE4331711A Expired - Lifetime DE4331711C2 (de) | 1992-09-18 | 1993-09-17 | Lösung zur Perfusion, Konservierung und Re-Perfusion von Organen |
Country Status (9)
| Country | Link |
|---|---|
| AT (1) | AT407216B (fr) |
| BE (1) | BE1007500A3 (fr) |
| CA (1) | CA2106249C (fr) |
| CH (1) | CH686870A5 (fr) |
| DE (1) | DE4331711C2 (fr) |
| ES (1) | ES2070089B1 (fr) |
| FR (1) | FR2695827B1 (fr) |
| GB (1) | GB2270614B (fr) |
| IT (1) | IT1272638B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19527734A1 (de) * | 1995-07-28 | 1997-01-30 | Hubert Verhaag | Verfahren und Vorrichtung zur Konservierung von Geweben und Organen, insbesondere von Transplantationsgeweben und -organen |
| US5880098A (en) * | 1996-04-12 | 1999-03-09 | Pharmacia & Upjohn Aktiebolag | Therapeutic treatment |
| SE9601396D0 (sv) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 2 |
| DE19706111C2 (de) * | 1997-02-17 | 1999-02-18 | Fresenius Medical Care De Gmbh | Lösung zur Aufbewahrung von Organen |
| US5834178C1 (en) * | 1997-07-09 | 2002-04-23 | Univ Wayne State | Flush-storage solution for donor organs |
| CN1057192C (zh) * | 1997-09-10 | 2000-10-11 | 上海长征医院 | 一种配制多器官保存液的方法 |
| DE19834087C1 (de) * | 1998-07-29 | 2000-03-30 | Mirzaie Sedaposhteh Massoud | Wäßrige Konservierungslösung und Verfahren zur Aufbewahrung tierischen Gewebes |
| FR2785501B1 (fr) | 1998-11-10 | 2001-01-05 | Centre Nat Rech Scient | Solution de perfusion et/ou de conservation et/ou de reperfusion lors de la transplantation d'organes |
| GB0028414D0 (en) | 2000-11-22 | 2001-01-03 | Univ Leeds | Flush preservation solution |
| US20060078872A1 (en) * | 2004-10-12 | 2006-04-13 | Atsushi Taguchi | Cell-preservation liquid |
| WO2007128866A2 (fr) * | 2006-05-09 | 2007-11-15 | Novobion Oy | Nouvelles compositions chimiques |
| JP2016516830A (ja) * | 2013-04-24 | 2016-06-09 | ソマールション・エルエルシー | 酸素含有量が増加され、安定性が向上され、貯蔵寿命が長くなった臓器及び組織の保存溶液 |
| US20160088832A1 (en) * | 2013-04-29 | 2016-03-31 | Somahlution, Llc | Formulations containing poly (0-2 hydroxyethyl) starch for increasing the oxygen-content, stability and shelf life of an organ and tissue preservation solution |
| EP3027016B1 (fr) | 2013-11-22 | 2019-06-12 | Somahlution, LLC | Solutions pour augmenter la stabilité et la durée de vie en stockage d'une solution de conservation d'organe et de tissu |
| CN115720893B (zh) * | 2022-08-08 | 2024-02-23 | 四川大学华西医院 | 一种甲状旁腺体外保存液和保存方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4138040A1 (de) * | 1990-11-20 | 1992-05-21 | Pasteur Merieux Serums Vacc | Loesungen fuer die perfusion, konservierung und reperfusion von organgen |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4798824A (en) * | 1985-10-03 | 1989-01-17 | Wisconsin Alumni Research Foundation | Perfusate for the preservation of organs |
| US4879283A (en) * | 1985-10-03 | 1989-11-07 | Wisconsin Alumni Research Foundation | Solution for the preservation of organs |
| ES2007994A6 (es) * | 1988-08-16 | 1989-07-01 | Grino Boira Jose Maria | Medio liquido para perfusion y preservacion de organos. |
| US4920044A (en) * | 1988-11-08 | 1990-04-24 | The Cleveland Clinic Foundation | Intracellular flush solution for preserving organs |
| US4938961A (en) * | 1989-04-28 | 1990-07-03 | Geoffrey Collins | Organ preservation solution containing pokyethylene gycol and method of performing cardioplegia |
| US5104787A (en) * | 1990-03-05 | 1992-04-14 | Lindstrom Richard L | Method for apparatus for a defined serumfree medical solution useful for corneal preservation |
| US5145771A (en) * | 1990-04-12 | 1992-09-08 | The University Of North Carolina At Chapel Hill | Rinse solution for organs and tissues |
| GB9021325D0 (en) * | 1990-10-01 | 1990-11-14 | Geistlich Soehne Ag | Chemical composition |
-
1993
- 1993-09-14 BE BE9300965A patent/BE1007500A3/fr not_active IP Right Cessation
- 1993-09-14 FR FR9310926A patent/FR2695827B1/fr not_active Expired - Lifetime
- 1993-09-14 CH CH02760/93A patent/CH686870A5/fr not_active IP Right Cessation
- 1993-09-15 CA CA002106249A patent/CA2106249C/fr not_active Expired - Lifetime
- 1993-09-16 IT ITMI931994A patent/IT1272638B/it active IP Right Grant
- 1993-09-17 DE DE4331711A patent/DE4331711C2/de not_active Expired - Lifetime
- 1993-09-17 ES ES09301971A patent/ES2070089B1/es not_active Expired - Fee Related
- 1993-09-17 GB GB9319264A patent/GB2270614B/en not_active Expired - Lifetime
- 1993-09-20 AT AT0189793A patent/AT407216B/de not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4138040A1 (de) * | 1990-11-20 | 1992-05-21 | Pasteur Merieux Serums Vacc | Loesungen fuer die perfusion, konservierung und reperfusion von organgen |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2695827A1 (fr) | 1994-03-25 |
| DE4331711A1 (de) | 1994-03-24 |
| CA2106249A1 (fr) | 1994-03-19 |
| AT407216B (de) | 2001-01-25 |
| FR2695827B1 (fr) | 1995-07-28 |
| GB2270614B (en) | 1996-03-20 |
| ES2070089B1 (es) | 1995-12-16 |
| IT1272638B (it) | 1997-06-26 |
| CH686870A5 (fr) | 1996-07-31 |
| GB9319264D0 (en) | 1993-11-03 |
| ITMI931994A0 (it) | 1993-09-16 |
| CA2106249C (fr) | 2009-04-14 |
| GB2270614A (en) | 1994-03-23 |
| ATA189793A (de) | 2000-06-15 |
| ES2070089A1 (es) | 1995-05-16 |
| ITMI931994A1 (it) | 1995-03-16 |
| BE1007500A3 (fr) | 1995-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4331711C2 (de) | Lösung zur Perfusion, Konservierung und Re-Perfusion von Organen | |
| DE3843958C2 (de) | Zusammensetzung für die Konservierung und Lagerung eines Organtransplantats und Verfahren zu dessen Konservierung | |
| DE69126861T2 (de) | Lösung zur aufbewahrung roter blutzellen | |
| DE3303860C2 (fr) | ||
| DE60102359T2 (de) | Verfahren und zusammensetzung für organ- und gewebekonservierung sowie für hypothermischen blutersatz | |
| DE69224416T2 (de) | Stabilisierte PVP-I Lösungen | |
| DE60131189T2 (de) | Spül- und konservierungslösung | |
| DE69226184T2 (de) | Hypertone isochlorämische formulierung zur behandlung des kreislaufschocks | |
| DE69410634T2 (de) | Anatomisches und biologisches konservierungsmittel und verbesserte einbalsamierungszusammensetzung und -verfahren | |
| DE102005031532A1 (de) | Lagermedium für Zellen | |
| EP1859679B1 (fr) | Solution protectrice destinée à éviter les lésions ischémiques | |
| DE69314032T2 (de) | Flüssigkeit zur konservierung von organen | |
| DE3722984A1 (de) | Waessrige loesung zum suspendieren und lagern von zellen, insbesondere erythrozyten | |
| DE69303343T2 (de) | Zusammensetzung und Verfahren zur Blutkonservierung | |
| DE4138040A1 (de) | Loesungen fuer die perfusion, konservierung und reperfusion von organgen | |
| EP2154956A2 (fr) | Solutions pour la transfusion et la conservation d'organes et de tissus | |
| DE69103427T2 (de) | Chemische zusammensetzungen. | |
| EP0012272B1 (fr) | Solution protégeant le coeur et les reins et procédé pour sa préparation | |
| DE69122122T2 (de) | Hydroxamsäuren zur prävention von peperfusionsschäden | |
| DE3707999A1 (de) | Verwendung von oxypurinol zur verminderung von zellschaeden | |
| DE1667900C3 (de) | Schnell wirkende, beständige Rinderinsulinlösung | |
| DE69426295T2 (de) | Organkonservierungsmittel | |
| DE2733578A1 (de) | Intravenoese mittel, verfahren zu deren herstellung sowie deren verwendung | |
| DE932146C (de) | Verfahren zur Herstellung von stabilisierten, waessrigen Hyaluronidase-Loesungen | |
| DE2022898C3 (de) | Verfahren zur Verhinderung der Verfärbung von Lecithin beim Sterilisieren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8127 | New person/name/address of the applicant |
Owner name: IMTIX SANGSTAT, LYON, FR |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| R071 | Expiry of right | ||
| R071 | Expiry of right |